5CMZ
 
 | | Artificial HIV fusion inhibitor AP3 fused to the C-terminus of gp41 NHR | | Descriptor: | 1,2-ETHANEDIOL, 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE, Artificial HIV entry inhibitor AP3, ... | | Authors: | Zhu, Y, Ye, S, Zhang, R. | | Deposit date: | 2015-07-17 | | Release date: | 2015-09-16 | | Method: | X-RAY DIFFRACTION (2.574 Å) | | Cite: | Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Sci Rep, 5, 2015
|
|
5CN0
 | | Artificial HIV fusion inhibitor AP2 fused to the C-terminus of gp41 NHR | | Descriptor: | DI(HYDROXYETHYL)ETHER, Envelope glycoprotein,AP2, MAGNESIUM ION | | Authors: | Zhu, Y, Ye, S, Zhang, R. | | Deposit date: | 2015-07-17 | | Release date: | 2015-09-16 | | Last modified: | 2024-03-20 | | Method: | X-RAY DIFFRACTION (1.901 Å) | | Cite: | Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Sci Rep, 5, 2015
|
|
5CMU
 | |
5VL7
 | | PCSK9 complex with Fab33 | | Descriptor: | Fab33 heavy chain, Fab33 light chain, Proprotein convertase subtilisin/kexin type 9 | | Authors: | Eigenbrot, C, Shia, S. | | Deposit date: | 2017-04-25 | | Release date: | 2017-08-16 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (3.5 Å) | | Cite: | Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists.
Nat. Struct. Mol. Biol., 24, 2017
|
|
5W53
 | |
5W6U
 | |
5W5U
 | |
5W6T
 | |
5VOE
 | | DesGla-XaS195A Bound to Aptamer 11F7t | | Descriptor: | Aptamer 11F7t (36-MER), CALCIUM ION, Coagulation factor X, ... | | Authors: | Gunaratne, R, Kumar, S, Frederiksen, J.W, Stayrook, S, Lohrmann, J.L, Perry, K, Chabata, C.V, Thalji, N.K, Ho, M.D, Arepally, G, Camire, R.M, Krishnaswamy, S.K, Sullenger, B.A. | | Deposit date: | 2017-05-02 | | Release date: | 2018-06-20 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.
Nat. Biotechnol., 36, 2018
|
|
5W6I
 | |
5W41
 | |
5W5S
 | |
5W6R
 | |
8CSA
 | |
1C1Z
 | | CRYSTAL STRUCTURE OF HUMAN BETA-2-GLYCOPROTEIN-I (APOLIPOPROTEIN-H) | | Descriptor: | 2-acetamido-2-deoxy-alpha-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, BETA2-GLYCOPROTEIN-I, ... | | Authors: | Schwarzenbacher, R, Zeth, K, Diederichs, K, Gries, A, Kostner, G.M, Laggner, P, Prassl, R. | | Deposit date: | 1999-07-22 | | Release date: | 1999-11-19 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.87 Å) | | Cite: | Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome.
EMBO J., 18, 1999
|
|
5OHV
 | | K33-specific affimer bound to K33 diUb | | Descriptor: | GLYCEROL, K33-specific affimer, SULFATE ION, ... | | Authors: | Michel, M.A, Komander, D. | | Deposit date: | 2017-07-18 | | Release date: | 2017-10-04 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (2.801 Å) | | Cite: | Ubiquitin Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin Signaling.
Mol. Cell, 68, 2017
|
|
5OMM
 | |
5UEI
 | | Crystal Structure of Variable Lymphocyte Receptor (VLR) O13 (Apo) | | Descriptor: | CHLORIDE ION, GLYCEROL, O13 | | Authors: | Gunn, R.J, Collins, B.C, McKitrick, T.R, Cummings, R.D, Herrin, B.R, Cooper, M.D, Wilson, I.A. | | Deposit date: | 2017-01-02 | | Release date: | 2017-10-18 | | Last modified: | 2019-12-11 | | Method: | X-RAY DIFFRACTION (1.702 Å) | | Cite: | Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates.
Structure, 25, 2017
|
|
5UF4
 | | Crystal Structure of Variable Lymphocyte Receptor (VLR) O13 with LNnT bound | | Descriptor: | O13, beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-beta-D-galactopyranose-(1-4)-alpha-D-glucopyranose | | Authors: | Gunn, R.J, Collins, B.C, McKitrick, T.R, Cummings, R.D, Cooper, M.D, Herrin, B.R, Wilson, I.A. | | Deposit date: | 2017-01-03 | | Release date: | 2017-10-18 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.04 Å) | | Cite: | Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates.
Structure, 25, 2017
|
|
5UFD
 | | Crystal Structure of Variable Lymphocyte Receptor (VLR) RBC36 (Apo) | | Descriptor: | MAGNESIUM ION, RBC36 | | Authors: | Collins, B.C, Gunn, R.J, McKitrick, T.R, Herrin, B.R, Cummings, R.D, Cooper, M.D, Wilson, I.A. | | Deposit date: | 2017-01-04 | | Release date: | 2017-10-18 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.696 Å) | | Cite: | Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates.
Structure, 25, 2017
|
|
5NZB
 | |
5UF1
 | | Crystal Structure of Variable Lymphocyte Receptor (VLR) O13 in complex with H-trisaccharide | | Descriptor: | CHLORIDE ION, O13, alpha-L-fucopyranose-(1-2)-beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose | | Authors: | Gunn, R.J, Collins, B.C, McKitrick, T.R, Cummings, R.D, Cooper, M.D, Herrin, B.R, Wilson, I.A. | | Deposit date: | 2017-01-03 | | Release date: | 2017-10-18 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.03 Å) | | Cite: | Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates.
Structure, 25, 2017
|
|
5O9M
 | | Crystal structure of human Histamine-Releasing Factor (HRF/TCTP)containing a disulphide-linked dimer | | Descriptor: | DI(HYDROXYETHYL)ETHER, Translationally-controlled tumor protein | | Authors: | Dore, K.A, Kashiwakura, J, McDonnell, J.M, Gould, H.J, Kawakami, T, Sutton, B.J, Davies, A.M. | | Deposit date: | 2017-06-19 | | Release date: | 2017-12-20 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (1.4 Å) | | Cite: | Crystal structures of murine and human Histamine-Releasing Factor (HRF/TCTP) and a model for HRF dimerisation in mast cell activation.
Mol. Immunol., 93, 2017
|
|
5UFC
 | | Crystal Structure of Variable Lymphocyte Receptor (VLR) Tn4-22 with H-trisaccharide bound | | Descriptor: | Tn4-22, alpha-L-fucopyranose-(1-2)-beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose | | Authors: | Collins, B.C, Gunn, R.J, McKitrick, T.R, Cummings, R.D, Cooper, M.D, Herrin, B.R, Wilson, I.A. | | Deposit date: | 2017-01-04 | | Release date: | 2017-10-18 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.888 Å) | | Cite: | Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates.
Structure, 25, 2017
|
|
5O9L
 | | Crystal structure of human Histamine-Releasing Factor (HRF/TCTP) | | Descriptor: | Translationally-controlled tumor protein | | Authors: | Dore, K.A, Kashiwakura, J, McDonnell, J.M, Gould, H.J, Kawakami, T, Sutton, B.J, Davies, A.M. | | Deposit date: | 2017-06-19 | | Release date: | 2017-12-20 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (1.75 Å) | | Cite: | Crystal structures of murine and human Histamine-Releasing Factor (HRF/TCTP) and a model for HRF dimerisation in mast cell activation.
Mol. Immunol., 93, 2017
|
|
